Futura Medical (LSE:FUM) reported revenue of £1.62 million for the first half of 2026, with a substantial portion generated by a settlement with former U.S. commercial partner Haleon.

Underlying royalty income from Eroxon remained modest during the period. The company ended the first half with cash of £1.24 million, which it said provides an operational cash runway until approximately October 2026 without additional funding.

Futura reduced its operating loss to £1.20 million during the period, while administrative expenses also declined following cost-reduction measures.

Market Performance Group appointed as U.S. Eroxon partner

Futura has revised its U.S. commercial arrangements for Eroxon by appointing Market Performance Group as its new partner in the market.

The company has also secured additional patents in China and the U.S. and consolidated its global manufacturing arrangements.

Futura is seeking additional funding and commercial partnerships as it develops its existing products and pipeline. Given its current cash position, the company will require further funding to extend operations beyond its stated runway.

Eroxon Intense targets production from early 2027

Futura reported positive home-user data for Eroxon Intense and has received clearance for an EU launch.

The company is also targeting U.S. Food and Drug Administration clearance for the product, while production is expected to begin in early 2027. FDA clearance has not yet been obtained based on the supplied information.

Futura is separately developing WSD4000, a female sexual health product range. The company reported feasibility and consumer study results and has begun early-stage discussions with potential partners across several major regions.

Futura Medical is a UK-based consumer healthcare company focused on sexual health products for men and women. Its portfolio includes Eroxon, an over-the-counter topical gel for erectile dysfunction, alongside the Eroxon Intense and WSD4000 development programmes.